Discovery and Development of Somatostatin Agonists

Peter Marbach, W. Bauer, David Bodmer, U. Briner, Christian Bruns, Ioana Lancranjan, Janos Pless, Friedrich Raulf, Barbara Stolz, Peter Vit,

Kluwer Academic Publishers eBooks · 2006 · 12 citations · 56 references

Concepts

Abstract

Somatostatin was discovered in the laboratories of Professor R. Guillemin at the Salk Institute in La Jolla, California (Brazeau et al., 1973; Guillemin, 1992), and was first described as hypothalamic growth hormone (GH)-release inhibiting factor. Within a few years, more and more information accumulated about its ubiquitous distribution in different regions of the body, including the pancreas and gastrointestinal tract, and on its more general inhibitory functions on hormones such as insulin, glucagon, gastrin, and other gastrointestinal hormones, as well as on enzymes such as those from the exocrine pancreas. These characteristics suggested that somatostatin had enormous therapeutic potential, and early clinical investigations substantiated hopes for applications in the treatment of hypersecretory states

References

56